Search Results

Containing any of the words

Only of the type

A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk Drug Clinical Trial

UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection – A retrospective analysis (UNCOVER) Drug Clinical Trial

A double blind, Double Dummy, Randomized, Multi-Centre study to assess the tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy with Metformin in Muslim Patients with Type 2 Diabetes Fasting During Ramadan. Drug Clinical Trial

A multicentre, prospective observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan Drug Clinical Trial

A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD) Drug Clinical Trial

An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting Drug Clinical Trial

A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin Drug Clinical Trial

Daily practice treatment and Influence of Visanne on the patient Assessment of quality of life parameters Drug Clinical Trial

A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) Drug Clinical Trial

A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly. Drug Clinical Trial